Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06905327
PHASE1

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.

Official title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered QCZ484 in Healthy Subjects and Subjects With Mild Hypertension

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

56

Start Date

2023-03-08

Completion Date

2025-07-01

Last Updated

2026-07-09

Healthy Volunteers

Yes

Interventions

DRUG

QCZ484

doses of 50, 150, 300 or 600 mg via subcutaneous injection

DRUG

Placebo

via subcutaneous injection

Locations (4)

Novartis Investigative Site

Herston, Queensland, Australia

Novartis Investigative Site

Morayfield, Queensland, Australia

Novartis Investigative Site

Adelaide, Australia

Novartis Investigative Site

Auckland, New Zealand